The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Immunoglobulin A nephropathy (IgAN), also called Berger's disease, is an autoimmune disease that damages your kidneys. This condition happens when antibodies (specifically IgA) build up and form ...

The trial assessed the safety and efficacy of the therapy against placebo in patients with IgAN. Subjects treated with the therapy in conjunction with a RAS inhibitor experienced a reduction of 36 ...

These quiz questions about immunoglobulin A nephropathy (IgAN) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your physician ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

IgAN is a common, chronic autoimmune kidney disease that primarily affects young adults. In patients with the disease, a protein called immunoglobulin A (IgA) becomes trapped in the filters of the ...